{{Rsnum
|rsid=1051685
|Gene=XRCC5
|Chromosome=2
|position=216205653
|Orientation=plus
|GMAF=0.1433
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=XRCC5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 77.9 | 22.1 | 0.0
| HCB | 83.2 | 15.3 | 1.5
| JPT | 82.1 | 17.9 | 0.0
| YRI | 40.1 | 46.9 | 12.9
| ASW | 42.1 | 49.1 | 8.8
| CHB | 83.2 | 15.3 | 1.5
| CHD | 81.7 | 15.6 | 2.8
| GIH | 63.4 | 29.7 | 6.9
| LWK | 46.4 | 46.4 | 7.3
| MEX | 82.8 | 15.5 | 1.7
| MKK | 57.7 | 35.9 | 6.4
| TSI | 75.5 | 24.5 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=21435719
|Title=Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide
}}

{{PMID|16465622|OA=1
}} Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.

{{PMID|17901044}} Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma.

{{PMID|18579371|OA=1
}} Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions.

{{PMID|18768505|OA=1
}} Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}